Home › NDC Lookup › RxCUI directory › RxCUI 2736939

Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML Ophthalmic Solution [Yuvezzi] — RxCUI 2736939

Name: Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML Ophthalmic Solution [Yuvezzi] (RxCUI 2736939)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2736939 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2736939

Official nameBrimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML Ophthalmic Solution [Yuvezzi]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asYuvezzi (brimonidine tartrate 0.1 % / carbachol 2.75 % ) Ophthalmic Solution; YUVEZZI 2.75 % / 0.1 % Ophthalmic Solution

FDA products mapped1

Package NDCs mapped2

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Brimonidine Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Brimonidine eye drops are used to lower the pressure inside your eye — what doctors call intraocular pressure. High eye pressure is a key risk factor for glaucoma-related vision da...
What exactly is brimonidine eye drops used for?
The usual routine is one drop in the affected eye or eyes, three times a day — roughly 8 hours apart, so think morning, afternoon, and evening. If you use other eye drops too, wait...
The most common ones are eye redness, itching, a burning or stinging sensation, and dry mouth. Some people also notice drowsiness or blurred vision. These are usually manageable, b...

📖 Read our full Brimonidine Ophthalmic guide →

🕸️ Concept Web — How Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML Ophthalmic Solution [Yuvezzi] RxCUI 2736939 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Brimonidine 134615 IN
- Carbachol 1999 IN
- Brimonidine / carbachol 2736928 MIN
- Brimonidine tartrate 39171 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Yuvezzi 2736934 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Brimonidine / carbachol Ophthalmic Solution 2736930 SCDF
- Brimonidine tartrate / carbachol Ophthalmic Solution 2736932 SCDFP
- Brimonidine / carbachol Ophthalmic Product 2736929 SCDG
- Brimonidine tartrate / carbachol Ophthalmic Product 2736931 SCDGP
- Brimonidine / carbachol Ophthalmic Solution [Yuvezzi] 2736937 SBDF
- Brimonidine tartrate / carbachol Ophthalmic Solution [Yuvezzi] 2736938 SBDFP
- Yuvezzi Ophthalmic Product 2736936 SBDG
- Ophthalmic Solution 7670 DF
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML Ophthalmic Solution 2736933 SCD
- Brimonidine tartrate 1 MG/ML 861203 SCDC
- Carbachol 27.5 MG/ML 2736927 SCDC
- Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML [Yuvezzi] 2736935 SBDC

Showing up to 8 concepts per family — 17 of 18 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML Ophthalmic Solution SCD · 2736933
Brimonidine tartrate 1 MG/ML SCDC · 861203
Carbachol 27.5 MG/ML SCDC · 2736927
Brimonidine / carbachol Ophthalmic Solution SCDF · 2736930
Brimonidine tartrate / carbachol Ophthalmic Solution SCDFP · 2736932
Brimonidine / carbachol Ophthalmic Product SCDG · 2736929
Brimonidine tartrate / carbachol Ophthalmic Product SCDGP · 2736931

Brand-Name Concepts

Brimonidine tartrate 1 MG/ML / carbachol 27.5 MG/ML [Yuvezzi] SBDC · 2736935
Brimonidine / carbachol Ophthalmic Solution [Yuvezzi] SBDF · 2736937
Brimonidine tartrate / carbachol Ophthalmic Solution [Yuvezzi] SBDFP · 2736938
Yuvezzi Ophthalmic Product SBDG · 2736936
Yuvezzi BN · 2736934

📦 FDA Products & Package NDCs

1 product · 2 package NDCs

2 package NDCs map to RxCUI 2736939 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
84892-0275-30	6 POUCH in 1 CARTON (84892-275-30) / 5 VIAL, SINGLE-DOSE in...	YUVEZZI	Visus Therapeutics, Inc.	2026-02-18
84892-0275-99	1 POUCH in 1 CARTON (84892-275-99) / 5 VIAL, SINGLE-DOSE in...	YUVEZZI	Visus Therapeutics, Inc.	2026-02-18

Observed labelers: Visus Therapeutics, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.